The Leader in Autologous Fibroblast Therapies

At the forefront of personalized biologics 

Castle Creek Biosciences, Inc., a privately held, clinical-stage cell and gene therapy company, is focused on developing and commercializing disease-modifying therapies for patients suffering from orphan conditions where there are high unmet needs due to a lack of available treatment options. Our approach to personalized biologics is distinctive based on our proprietary, autologous fibroblast technology platform. By extracting fibroblast cells from a patient’s own skin, we create localized treatments that are compatible with the unique biology of each patient and have the potential to address the underlying cause of disease.

Our Mission

To leverage the science behind our proprietary, autologous fibroblast technology platform and manufacturing experience to create transformative cell and gene therapies and improve the lives of patients suffering from orphan conditions with high unmet medical needs.

Our Commitment to Life Science Innovation

Castle Creek Biosciences is a portfolio company of Paragon Biosciences.

Recognized as a life science innovator, Paragon creates, invests in and builds life science companies in artificial intelligence, cell and gene therapy, synthetic biology and biopharmaceuticals. Paragon’s current portfolio includes Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by its replicable Paragon Innovation Capital™ model. Paragon stands at the intersection of human need, life science, and company creation.

Our Inspiration

We are inspired by people impacted by orphan conditions with high unmet medical needs who currently have few or no treatment options. Our current focus is on dystrophic epidermolysis bullosa (DEB) and localized scleroderma, and the goal of expanding our platform to other therapeutic areas.